Trial Profile
The long-term efficacy and safety of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes, who had been treated with a glinid.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2011
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SINGLE Study 2
- 06 Apr 2011 New trial record